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Abstract	  
Master thesis, programme in Medicine, 2015. 
Sara Elofsson, Department of Molecular and Clinical Medicine, Institute of Medicine, 
University of Gothenburg, Sweden.  
Previous clinical studies and in vitro experiments have confirmed that treatment with 
adrenocorticotropic hormone (ACTH) have ameliorating effects on nephrotic 
syndrome. This action is believed to be mediated by stimulation of Melanocortin-1 
Receptor (MC1R) in podocytes. The full extent of MC1R signalling in podocytes is 
still unknown, but the anti-oxidative enzyme catalase has been found to be one of the 
downstream effectors. We have studied in what ways catalase is regulated to exert its 
action and what effect this activity has in podocytes. In addition, we studied the 
human constitutively active MC1R-mutant, E94K.  
Cultured differentiated mouse podocytes were transduced with different lentivirus to 
overexpress MC1R or the constitutively active MC1R-mutant. The podocytes were 
subjected to different concentrations of a nephrotoxic agent, puromycin, and/or the 
known MC1R agonist BMS-470539. In addition, a catalase specific inhibitor, 3-
amino-1, 2, 4-triazole, was used to elucidate whether the protective effects of MC1R 
stimulation is dependent on catalase. The effects due to different treatments on the 
podocytes were assessed with diverse analytical assays.  
The human constitutive MC1R-mutant did not show an effect in the range we 
expected and the mouse mutant will be tested hereafter. The inhibitor gave a dose-
dependent inhibition but had an unsuspected interaction with puromycin.  
In summary, catalase still seems to have a possible role in the ameliorating effects of 
MC1R-stimulation in nephrotic syndrome and these experiments have given new 
strategies and developed better implements to future experiments.   
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Introduction	  
The	  Kidney	  
The kidneys are important in the process of regulating the balance and components of 
the body fluid [1, 2]. By producing 180 litres of primary urine per day: fluid, acid-
base and electrolyte levels are regulated at the same time as waste products are being 
eliminated, through urine excretion. This filtration occurs in the smallest functional 
unit of the kidney, the nephron. Each kidney has about one million nephrons and one 
of the important components of each nephron is the glomerulus. In the glomerulus the 
blood is filtrated over the glomerular filtration barrier, comprised of four layers: 
endothelial cell surface layer (ESL), endothelial cells, glomerular basement 
membrane (GBM) and podocytes (see figure 1). These four components form a semi-
permeable and selective filtration space based on size, shape and charge of the 
passing molecule. The glomerulus also contains a structural supporting component, 
mesangial cells, which have no 
apparent role in the filtration.  
Podocytes	  
The podocytes are highly 
differentiated and specialized 
epithelial cells with an important role 
in the barrier. Between the podocytes are slit diaphragms (SD). The SD is a network 
of proteins that are connected to the actin cytoskeleton of the podocytes. They have 
the function to anchor the podocytes together and also to constitute the last barrier 
between blood and primary urine. The functions of the podocytes are dependent on 
morphology and require intact actin cytoskeleton to maintain foot processes and SD.  
 
Figure	  1	  [1]: The	  layers	  of	  the	  glomerular	  filtration	  barrier 
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Kidney	  disease	  
When the glomerular filtration barrier does not work as it should, a nephrotic 
syndrome might develop. The nephrotic syndrome includes proteinuria (> 3,5 g 
protein/day), hypoalbuminemia (< 30 g/L), hyperlipidemia, peripheral edema, 
increased tendency to create blood clots and increased sensibility to infections. This is 
a nonspecific disorder with most commonly an idiopathic origin but some are known 
and further categorized from morphological changes of the kidney, through biopsy. 
The most common is membranous nephropathy, MN, with an incidence of 5-10 per 
million population and year [3]. 
In 80 % of the patients a nephrotic syndrome is present when the diagnosis of MN is 
defined [3]. With urine samples the presence and level of proteinuria can be clarified 
along with the degree of hematuria. The kidney function is also measured with blood 
samples of creatinine, urea and albumin together with calculation of glomerular 
filtration rate (GFR) through 51 Cr-EDTA-clearance, iohexol-clerance or estimated 
GFR. Other blood samples are also controlled such as haemoglobin, leukocytes, 
thrombocytes, electrolytes, liver function tests, lipids, circulating antibodies and 
complement factors.  
MN is either idiopathic or secondary due to system diseases, cancer, infections, drugs 
or toxic agents. Anamnestic questions are important to define which type that is most 
likely, but the investigations are not just performed to define this but also elucidate 
the grade of severity. With a biopsy of the kidney the morphology of the glomeruli 
are visualized, together with subepithelial deposits in electron microscope and IgG-
complexes with immunofluorescence.  
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Pathological components in MN are subepithelial deposits of immune complexes 
(IgG; IgG4 in idiopathic MN), capillary wall thickening, foot processes effacement 
and GBM thickening (see figure 2) [2].  
70 % of the patients 
with idiopathic MN 
have autoantibodies to a 
receptor, on the cell 
surface of the podocytes, 
called phospholipase-A2 
(PLA2R) [3]. When the 
circulating 
autoantibodies pass from the blood through the endothelial cells to the GBM they 
bind to PLA2R on the podocytes and form immune complexes. These immune 
complexes recruit the C5b-9 membrane attack complex (MAC) from the system of 
complement factors. MAC is inserted into the podocyte cell membrane and this 
initiates multiple intracellular signalling cascades with production of reactive oxygen 
species (ROS), alterations of SD-proteins and actin cytoskeleton, activation of nuclear 
factor kappa B (NF-κB) and effects on mitogen-activated protein kinase (MAPK) 
pathways including p38, extracellular signal-regulated kinase (ERK) and c-Jun N-
terminal kinase (JNK). The result of these processes are foot process effacement and 
proteinuria [2, 4].  
The natural course of the idiopathic disease is highly varied: some have a spontaneous 
remission and other go quickly to uremia, while some remains with nephrotic 
syndrome but with preserved GFR through years. Treatments of idiopathic MN 
without nephrotic syndrome are only symptomatic with efforts to reduce proteinuria 
 
Figure	  2	  [2]:	  Circulating	  autoantibodies	  against	  PLA2R	  passes	  the	  endothelial	  cells	  (EC)	  
and	  form	  immune	  complexes	  together	  with	  PLA2R.	  The	  immune	  complexes	  stimulate	  
C5b-­‐9	  to	  be	  inserted	  to	  the	  podocytes	  and	  initiate	  intracellular	  cascades	  with	  reactive	  
oxygen	  species	  (ROS),	  effect	  mitogen-­‐activated	  protein	  kinase	  (MAPK),	  activate	  
nuclear	  factor	  kappa-­‐B	  (NF-­‐κB)	  and	  initiate	  creation	  of	  cytosolic	  phospholipase	  A2.	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and hopefully take control of the disease. Basal therapy is including ACE-inhibitor 
(lowering blood pressure and glomerular capillary hydrostatic pressure) and statins. 
These drugs are also given to the patients without nephrotic syndrome at the time of 
diagnosis. Further treatment in the aim of reach remission in proteinuria exists of a 
combination of different immunomodulatory drugs: cyclosporine, glucocorticoids and 
chemotherapy (primarily alkylating, such as cyclophosphamide or chlorambucil). 
Glucocorticoids alone do rarely show any effect. Considering the discovery of 
autoantibodies the treatment with monoclonal antibodies against B-cells (rituximab) 
has become an alternative. In some cases treatment with adrenocorticotropic hormone 
(ACTH) is being used with beneficial results [3]. Previous in vivo experiments have 
confirmed that ACTH-treatment reduces proteinuria (50-60%), lowers oxidative stress 
and leads to improved glomerular morphology by promoting a re-establishment of the 
podocyte foot processes [2, 4, 5]. Despite the low doses used the stimulation of the 
adrenal glands by ACTH is enough to release cortisol in such amount that Cushingoid 
side effects occur, for example osteoporosis, hypertension and edema [2]. The 
secondary type of MN is treated by targeted treatment against the specific underlying 
cause. 
Melanocortin-­‐1	  Receptor	  and	  ACTH	  
 ACTH is a known ligand for Melanocortin-1 
receptors (MC1R), which is the first of five 
melanocortin receptor-subtypes [2]. They are G-
protein-coupled 7 transmembrane receptors. 
MC1R is mainly known considering its 
expression in melanocytes, where it acts in the regulation of skin pigmentation. 
Stimulation of the receptor is involved in the defence against oxidative stress, due to 
 
Figure 3: Downstream effects of MC1R 
Master Thesis, Programme in Medicine  Sara Elofsson 
Melanocortin-1 Receptor-Stimulation and its Downstream Effector Mechanisms in Podocytes	  
9 
UV-radiation, by activation of the antioxidant enzyme catalase. Sequent, mutations of 
MC1R are a possible part of an increased risk of melanoma. Furthermore, the MC1R 
is known to possess anti-inflammatory properties, through its expression on immune 
cells [2]. 
Activation of MC1R in the cell membrane of podocytes has in previous studies [2] 
been shown to involve adenylyl cyclase (AC), activation of MAP kinases p38 and 
ERK1/2 due to phosphorylation, inhibition of NF-κB and activation of catalase (see 
figure 3). Increased levels of cAMP activate protein kinase A (PKA), which leads to 
binding of cAMP responsive element-binding protein (CREB) to cAMP response 
elements (CRE) in the DNA. This pathway has been shown to be important in 
melanocytes, but it may not be crucial for normalization of podocyte function. To 
better understand the ameliorating effects of ACTH it is of great interest to determine 
the full extent of the signalling pathways and mechanisms of MC1R.  
Melanocortin-­‐1	  receptor-­‐mutants	  
The in vitro podocyte MC1R-mutants have mutations where residues at specific 
positions are exchanged to positively charged ones giving them a constitutive MC1R 
activity, which is not dependent on an activation signal in terms of a ligand. The 
mouse and human MC1R-mutant are called E92K and E94K, respectively. The mouse 
mutant has been described in an article by Benned-Jensen et al, 2011 [6], where they 
analysed the activity initiated from each receptor by measuring the amount of 
accumulated cAMP in the cells. Like the regular MC1R an accumulation of cAMP is 
a downstream effect owing to receptor activity and the concentration of cAMP is 
therefore correlated to the degree of activity. The activity of the mouse mutant is 
about 50 % of the activity that normally would follow after high stimulation of 
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MC1R. With the mouse mutant, in contrast to wild-type (wt) MC1R, the 
accumulation of cAMP increases independently of agonist.  
Few published studies have been done on the human constitutive MC1R-mutant, but 
measurement of CREB activation, which reflects long-term changes in cAMP-levels, 
has been done [6]. The human constitutive MC1R-mutant had a CREB-activity two 
and a half times higher than normal MC1R expressing cells. This means that both the 
mouse and human mutants gives a higher amount of cAMP than the regular MC1R. 
Catalase	  
Catalase is an anti-oxidative enzyme, which increases the intracellular defence against 
oxygen radical formations formed by ROS (reactive oxygen species). Catalase 
catalyses the decomposition of hydrogen peroxide to water and oxygen. Stimulation 
of MC1R has been shown to increase the activity of catalase [5]. 
Hypothesis	  
We hypothesize that catalase plays an important role in the downstream pathway 
following Melanocortin-1 receptor stimulation in podocytes and that catalase is 
directly involved in the amelioration of nephrotic syndromes. 
Research	  question	  
With information about the MC1R and its downstream intracellular signalling effects, 
it might be possible to test new drugs specifically targeting the MC1R as a tool in 
treating patients with nephrotic syndrome. In this thesis I will focus on two aspects:  
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• The regulation of catalase and if this is through changes in the gene 
expression or effects on regulation mechanisms in protein level (activation, 
inhibition or degradation).  
• The possibility of using the constitutively active MC1R-mutant to simplify 
future experiments.  
Materials	  and	  Methods	  
Experiment made in preparation for this project was not done by me and are marked 
with an asterisk (*) and not further explained for this reason.  
Podocyctes	  
We used conditionally immortalized mouse podocytes (a kind gift from Dr Mundel at 
Massachusetts General Hospital, Boston, USA), which were cultured as previously 
described [7-9]. Differentiation of the podocytes proceeded 8-12 days before 
experiments and during this time the medium was changed every other or third day. 
Podocytes cultured for cAMP and catalase experiment were ended after 15-18 days 
after start of differentiation. The podocytes used in viability experiments with 
AlamarBlue® were ended at day 25-26 after start of differentiation. Podocytes were 
used in passages 13-19 at which point they maintained their pheno- and genotype. All 
studies were performed on differentiated podocytes. 
To modify podocytes to overexpress proteins and obtain different characteristics they 
were transduced with lentiviruses* combined with desired DNA-vector*. The DNA-
vector will integrate in the host cells and create an increased expression of this gene. 
In our experiments we used DNA-vectors to create an overexpression of MC1R, 
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MC1R-mutant or enhanced green fluorescent protein (EGFP; hereafter referred as 
virus control). The virus control was used to visualize that the lentiviruses do not have 
any effect themself. 
Pharmacological	  agents	  
Among the different identified agonists activating MC1R we used the highly specific 
and synthetic BMS-470539, described in previous studies [10-12]. BMS was 
synthetized after inquiry from Enamine (Enamine, Kiev, Ukraine). Henceforth BMS-
470539 is referred to as MC1R-agonist. The solvent Dimethyl Sulfoxide, DMSO, was 
used to solve the MC1R-agonist. To exclude that DMSO itself had any effect on the 
podocytes it was commonly used as a control in different experiments. Puromycin 
(puromycin aminonucleoside; Sigma Aldrich Sweden, Stockholm, Sweden) is the 
aminonucleoside portion of puromycin (antibiotics) and is used both in vivo and in 
vitro studies to model nephrotic syndrome [13]. Through actin disruption puromycin 
rearranges the actin cytoskeleton and thereby induces nephropathy. The medium used 
to feed the podocytes in the cell culture constitute of RPMI 1640 (Sigma-Aldrich®) 
Penicillin-Streptomycin, to prevent bacterial contamination, and 10 % Fetal Bovine 
Serum, FBS. 
Catalase	  experiments	  
Due to having several kinds of different catalase experiments, I have divided them in 
four parts (1-4). In the first part, we evaluated the possibility about an increased gene 
expression (catalase-mRNA) due to MC1R-stimulation. In part two, I searched for 
orienting background facts through theoretical article researches, to find potential 
further approach in how we can evaluate possible mechanism behind activation, 
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inhibition or degradation. In part three, we utilized the information I have found about 
the previous stated principles of regulation. Finally, in part four, we investigated the 
properties of the constitutive active MC1R mutant by analysing the catalase activity, 
the cAMP levels in the podocytes and the cell viability.  
1.	  Catalase	  mRNA-­‐expression	  
We used four different treatments on podocytes with MC1R or virus control, to 
compare the effects of each substance (see table 1). The podocytes representing the 
virus control have an endogenous (normal) expression of MC1R. The cells 
overexpressing MC1R has a much higher amount of functional MC1R-protein. The 
effects of MC1R-stimulation by the agonist will therefore be more distinct. The 
podocytes were incubated with the different treatments in 6, 24, 48 or 72 hours. 
Overview of the experimental treatments
 
Table 1: The two controls existed of PBS (Phosphate Buffered Saline), an isotonic water-based salt solution, or 1 % DMSO 
(Dimethyl Sulfoxide). The experiment podocytes were treated with 0,1 µM MC1R-agonist. One sample represents one well 
and there was the same amount of podocytes cultured in each well. The samples were analysed in duplicates. 
To examine the catalase expression level the amount of catalase mRNA were 
measured in harvested cell cultures with the different treatments. mRNA-purifications 
was done with RNeasy® (QIAGEN) and thereafter the RNA-concentrations of every 
sample were measured by using NanoDrop (Thermo Fisher Scientific Inc.). With 
these concentrations the volumes needed for cDNA-synthesis of each sample were 
calculated. cDNA is needed to be able to perform qPCR with Taqman® (Life 
Technologies Corporation, Thermo Fisher Scientific Inc.), where the gene-expression 
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of catalase can be analysed. To detect any difference between our samples with 
different treatments and a normal expression we compared them against the 
housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase, GAPDH. 
Housekeeping genes are genes that are stable in their expression at all times and 
therefore can be used to relate your genes to.  
The changes in mRNA-expression between controls and stimulated podocytes were 
calculated from the results from the qPCR. The Ct (cycle treshold) values define the 
amount of PCR-cycles necessary to get the fluorescent signal to exceed the 
background level. The Ct value is inversely proportional to the amount of nucleic 
acid, which means the lower Ct the higher expression of the gene in terms of mRNA 
copy number. The differences in Ct values between the gene of interest and the 
housekeeping gene (GAPDH) give us ΔCt and by using this we can compare different 
samples to each other normalized to differences in GAPDH. When calculating 
differences in ΔCt between control and stimulated groups we got ΔΔCt. If this is zero 
we do not have any differences between the groups and negative ΔΔCt values 
corresponds to an increase of the gene. Further calculation by using 2^-ΔΔCt 
visualizes changes of catalase gene expression between samples (fold change).  
2.	  Article	  research	  
This was done by going through articles found at the database PubMed, provided by 
National Center for Biotechnology Information (NCBI). The data about inhibition 
mechanisms are presented under Results but the remaining report is found in 
Appendices. 
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3.	  Inhibition	  of	  catalase	  activity	  
According to the results given from the article research about inhibition mechanisms, 
we had to evaluate the optimal application conditions of this mechanism in our 
experiments. To begin with, we had to determine the optimal concentration of the 
found catalase inhibitor, with regards to administration and ratio between desired 
effect and damage of the podocytes. With this information we expected to be able to 
optimize the use of the inhibitor in upcoming experiments. These podocytes were not 
transduced with any virus and therefore all of them had a normal expression of MC1R 
and hereafter named wild type (wt). Instead they were exposed to different 
concentrations of the catalase specific inhibitor (see table 2). By this experiment we 
analysed the inhibition capacity by comparing the catalase activity between podocytes 
exposed to different concentrations of the catalase specific inhibitor. The catalase 
activity was measured in the same procedure as below where the constitutive active 
mutant is analysed (see part 4). 
4.	  Evaluation	  of	  the	  constitutive	  MC1R	  mutant	  activity	  
Catalase	  activity	  
 Conditionally immortalized mouse podocytes were cultured in 6-well plates and 
transduced with three different types of lentivirus. The podocytes were made either 
normal expressive (virus control) or over expressive of MC1R or of the constitutively 
active MC1R-mutant (see table 3).  
Overview of the experimental treatments 
 
Table 2: Podocytes with normal expression of MC1R were treated with the catalase specific inhibitor in the concentrations of 0, 
5, 10 or 20 mM during 24, 48 or 72 hours. Each sample were analysed in triplicates. 
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To measure the protein concentration in each harvested sample we followed the 
protocol in BCA (Bicinchonicic acid)-assay Kit (Thermo Fisher Scentific Inc.). 
Thereafter the samples are visualized by measuring the absorbance at 562 nm on a 
plate reader (The SpectraMax® Plus 384 Microplate Reader). The results are 
summarized in the software (SoftMax® Pro). These concentrations were needed to 
calculate the volume of each sample to Amplex® Red catalase Assay Kit (Molecular 
Probes®). With the catalase assay we measured and compared the activity of catalase 
in the differently treated podocytes, normalized to total protein. The measurements 
were done by reading the fluorescence with a plate reader (Gemini XPS Microplate 
Reader) and the results were also in this case analysed with SoftMax® Pro. 
cAMP-­‐level	  
 To evaluate the constitutive MC1R-mutant we compared cAMP-levels in different 
podocytes, owing to the accumulation of cAMP due to MC1R-activation. The 
podocytes overexpressing the constitutive active mutant were compared to podocytes 
Overview of the experimental treatments 
 
Table 3: Theoretical layout of the different podocytes and their treatments. There were two plates of each podocyte type, 
which are described above. The low-expressive and MC1R transduced were treated with 10 nM MC1R-agonist during 0-96 
hours or 10 nM MC1R-agonist during 95 hours and thereafter 10 mM catalase inhibitor during one hour before harvesting. 
The constitutive MC1R mutant transduced podocytes were treated with DMSO during 0-96 hours or DMSO during 95 hours 
and then 10 mM catalase inhibitor during one hour, just like the earlier podocytes. Harvesting was done at the time of 0, 24, 
48, 72 and 96 hours. Each sample were analysed in triplicates. 
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of three other types: MC1R-overexpressive and normal MC1R-expressive with or 
without virus transduction (virus control and wt, respectively).  
The wild type and virus control are both used as controls to show that the podocytes 
themselves, or the virus do not have any effect on the cAMP-accumulation due to 
MC1R-stimulation. 
The podocytes were cultured in 6-well plates in all experiments and incubated with 
different treatments (see table 4). Afterwards we ran a cAMP-assay, cAMP-screen® 
System (Invitrogen®, Thermo Fisher Scientific Inc.) to measure the difference in 
activity in podocytes transduced with MC1R or the constitutive MC1R mutant.  
Cell	  viability	  
To visualize the cell viability AlamarBlue® (LIFE technologies, Stockholm, Sweden) 
were used. AlamarBlue® create a gradient of higher fluorescence with higher 
Overview of the experimental treatments 
 
Table 4: The experiments were done with culturing of the different podocytes in 6-wells plates. The two controls existed of medium 
(RPMI 1640, P/S and 0.1 % FBS) or DMSO (Dimethyl Sulfoxide), which is a solvent for MC1R-agonist; Forskolin and IBMX (3-
isobutyl-1-methylxanthone). The experiment podocytes were treated with the MC1R-agonist in different concentrations or the 
cAMP-activator Forskolin (FSK; positive control). In some experiments the concentration range of MC1R-agonist were between 
0.01 – 1000 nM and in some 0.1 – 10 000 nM. All podocytes were also treated with the phosphodiesterase inhibitor IBMX which 
prevent degradation of cAMP. All samples were analysed in duplicates. 
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viability. The active reagent is resazurin, a non-toxic, cell permeable compound 
which is blue and virtually non-fluorescent. When it has entered cells it will be 
converted to the fluorescent resorufin, which have an excitation at 530-560 nm and  
emission at 590 nm. All living cells have a natural capacity of this conversion and the 
degree of fluorescence stands in proportion to the amount of living cells. By 
measuring the increase in fluorescence the change in viability can be determined. We 
did the fluorescent readings day -3, 0, 3 and 8. At day 3 we saw the result of the 
different experiment mediums added after the reading at day 0. The different 
podocytes used were MC1R-expressing, constitutive MC1R-mutant-expressing and 
virus control. These were treated with experiment medium at day 0, just after the 
reading of fluorescence (see table 5). At day 3 the experiment medium was changed 
to regular medium and the podocytes had a recovery period of five days until the last 
Overview of the experimental treatments 
 
Table 5: The experiment medium contained DMSO 0.1% (control), 10 nM MC1R-agonist, 10 µg/ml puromycin, 20 µg/ml 
puromycin, 10µg/ml puromycin and 10 nM MC1R-agonist or 20 µg/ml puromycin and 10 nM MC1R-agonist. In the first and 
second experiment we added 20 nM catalase specific inhibitor to some plates one hour before the regular experiment 
medium at day 0 (after the reading). In the third experiment the podocytes were incubated with the inhibitor for 24 hours 
instead, from day 0 to day 1. Thereafter they got the regular experiment medium (without any extra reading at day 1)	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reading at day 8. Wells only containing alamar solution were used as blanks. The 
results will be normalized to the control of day 0 in respective experiment and the 
analysis will show percental differences between the wells. . 
Statistical	  methods	  
All raw data was summarized and gathered in Excel (Microsoft Office, ©Microsoft 
Corporation) to sort and/or make further calculations. With some raw data from the 
experiment runs I did graphs in GraphPad Prism® (©GraphPad Software Inc.) to 
easily visualize the results. Thereafter, to confirm eventual differences and if these 
were statistically significant I used analytical methods in Excel or GraphPad. 
Primarily I calculated p-values by using two-tailed type 2 student’s T-tests and to do 
that we assumed a normal distribution in all experiments. When comparing more than 
two groups, I used one-way ANOVA. I used two-tailed t-tests to not make 
preconceived assumptions or make reformulations of H0 (null hypothesis; a statement 
suggesting that every seen difference is due to chance until they are proven 
otherwise). With a two-tailed analysis I do not in advance determine which of the 
comparative groups that have the highest or lowest mean values. Type 2 is used 
because the comparing values come from different types of podocytes: MC1R-
overexpressing, constitutive active MC1R-mutant-overexpressing or normal 
expressing with or without virus. The different podocytes in comparison got same 
treatment with damaging or stimulating agents so the assays were to see if the 
divergent podocytes reacted different to these. The results are presented as mean ± 
s.e.m. if n ≥ 3. A calculation of results with n ≥ 3 and a p-value < 0.05 are considered 
statistically significant. A p-value < 0.05 is defined as * in the graphs and p-value < 
0.01 and <0.001 are defined as ** and ***, respectively. 
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Ethics	  
All experiments have been performed using mouse podocytes from Dr. Mundel’s Lab 
in Boston, MA. In the isolation and transformation of these cells from mice, the Lab 
in the US acted after approval of the Local Ethical Committee. The use of these cells, 
and the viral transfection of mutated or human proteins, does not require ethical 
permission. It does however require a special permit for laboratory work with virus 
that the Lab has. 
Results	  
1.	  Catalase	  mRNA-­‐expression	  
The mean fold change after six hours in both virus control and MC1R-podocytes were 
lower with stimulation by MC1R-agonist; 0.929 ± 0.06 and 0.832 ± 0.027 
respectively, compared to the 
six hours-controls with 1.022 
and 1.01 ± 0.045 respectively, 
(see graph 1). Consequently, 
the gene expression of catalase 
has been decreased due to 
stimulation during six hours. 
The podocytes overexpressing 
MC1R decreased even more 
than the virus controls.  
 
Graph 1: N = 5. Fold change in Catalase mRNA at the time of 6 hours between virus 
control and MC1R-podocytes, compared to respectively control at the same time. 
There is a non-significant decrease of mRNA in virus controls (p=0.3) and a 
significant decrease in MC1R-podocytes (p<0.01, **). 
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2.	  Article	  research	  
Inhibiting	  pathways	  
The most interesting facts I found in the articles were about the existence of the 
catalase specific inhibitor, 3-amino-1, 2, 4-triazole, 3-AT/AMT/ATZ (hereafter 
referred to as catalase inhibitor). This was the only inhibitor we found to be catalase 
specific [14].  
Aragon et al, 1991, observed brain and liver catalase in Male Long Evans rats, who 
got the catalase inhibitor administrated intraperitoneally [15]. They showed a dose- 
and time-dependent inhibition. The recovery of catalase activity in respective tissues 
was associated with the disappearance of the catalase inhibitor and consequently this 
was found to be an irreversible inhibitor. They also investigated the amounts of H2O2 
in the tissues and concluded a dependence of the catalase inhibitor activity and rate of 
generated H2O2. The catalase inhibitor seems to bind a compound of catalase and 
H2O2. Without H2O2 no inhibition is observed, neither does it inhibit in the presence 
of alcohol, because alcohol compete to bind the same site in the catalase-H2O2 
compound.  The difference between them is that the catalase inhibitor binds 
irreversibly [16]. Moreover, and on the contrary, they also refer to previous studies, 
including one by William RN et al [17] where they are suggesting the catalase 
inhibitor to be indirect in action rather than having a direct effect on catalase. 
According to this the catalase inhibitor would undergo metabolic transformation, in 
the topic tissue, to become an active inhibitor. 
To have guidance in reasonable administration doses of the catalase inhibitor directly 
to cells in cell culture further studies were investigated. Nenoi M. et al, 2001, used 
HP-100 cells (H2O2-resistant variants derived from human leukaemia HL60 cells) 
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which were incubated during 2 hours with the concentration of 25 mM the catalase 
inhibitor [18]. HP-100 cells were also used in another study by Hachiya M. et al, 
2005, and they incubated with 20 mM instead and during one hour [19].  
3.	  Inhibition	  of	  catalase	  activity	  
We tested four different concentrations and had measure points of catalase activity at 
the time of 24, 48 and 72 hours. I saw less catalase activity in all inhibitor-exposed 
podocytes compared to the podocytes not exposed to the inhibitor (control). There 
was an inhibitory effect with all concentrations in an almost perfect dose-dependent 
manner, except at 72 hours with 5 mM inhibitor (excluded in the graph). The higher 
concentration of the inhibitor, the lower level of catalase activity was observed (see 
graph 2). The lowest activity was seen at 24 hours and with time the catalase activity 
seems to recover. A later 
measure point has a mean 
activity of 109 % compared 
to the previous one. The 
activity at 24 hours of 
podocytes exposed to either 
10 mM or 20 mM 
correspondents to 65.2 % 
and 60.2 %, respectively, of 
the activity in controls at 
the same time. 
 
Graph 2: N = 2. The catalase activity decreased as the concentration of the inhibitor 
increased. At the time of 24 hours the biggest differences between controls and exposed 
podocytes were seen: 54.999 mU catalase compared to 35.857 and 33.122 mU catalase, 
respectively. The exposed podocytes had an activity of 65.2 % and 60.2 %, respectively, 
of the control activity at this time. The recover between two measure points gives an 
activity of 109 % compared to previous. mU correlates to the degree of catalase activity, 
as 1 U (unit) is defined as the required amount of catalase to decompose 1 µM H2O2 per 
minute at pH 7 at 25°C. 
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4.	  Evaluation	  of	  the	  constitutive	  MC1R	  mutant	  activity	  
Catalase	  activity	  
The degree of catalase activity in the 
different categories of podocytes was 
normalized to the starting value at zero 
hours, to show the development of the 
activity. Certain individual 
measurements could not be used due to 
technical problems, but no valid values 
were discarded. All starting values 
were correct and the normalization is 
thereby not impacted. 
 In the podocytes overexpressing 
MC1R, we saw an increased catalase activity due to stimulation with MC1R-agonist 
(see graph 3). At the time of 96 hours, the activity was 13.6 % higher compared to the 
starting point (p<0.001, ***). Contrary to our hypothesis the catalase activity in 
podocytes with MC1R-mutant remained unchanged. 
 
Graph 3: At the time of 96 hours the stimulated MC1R-podocytes had an 
activity at 113.6 %  ± 1.357 of starting value (n=4), compared to the activity 
of non-stimulated podocytes with MC1R-mutant at 99.22 % ± 3.819 (p = 
0.745, n=3). 
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Podocytes exposed to catalase specific inhibitor exhibited decreased levels of catalase 
activity compared to the controls 
at 96 hours (see graph 4). The 
MC1R-overexpressing podocytes 
had an activity of 59.64% and the 
podocytes with MC1R-mutant 
had an activity of 71.27% ± 
3.392 (p < 0.003). Comparison 
between MC1R and MC1R-
mutant shows a trend of less 
inhibition in the podocytes with 
MC1R-mutant. 
cAMP-­‐level	  
Podocytes overexpressing MC1R had a higher endogenous cAMP activity, and got an 
even higher concentration, of cAMP in response to MC1R-agonist stimulation with 
concentrations of 10 – 10 000 nM (see graph 5). The dose-dependent correlation had a 
statistical significance in the range of >10 nM (n = 4), with an exception at 10 000 nM 
MC1R-agonist which had to be excluded due to too few repeats (n = 2). The 
constitutive MC1R-mutant had a constitutive activity and did not answer to 
stimulation by MC1R-agonist in a range of 0,01 – 100 nM. Hovewer, with a 
concentration >100 nM even the constitutive MC1R mutant had a higher activity and 
showed a higher concentration of cAMP in dose-dependent manner.  
 
 
Graph 4: The catalase specific inhibitor decreases catalase activity in both 
podocytes with MC1R (A) and MC1R-mutant, respectively (B). All values are 
normalized to the starting value at 0 hours. Activity after exposure to catalase 
inhibitor compared to control at 96 hours (green bar) were 59.64% in MC1R-
podocytes (n=1) and 71.27% ± 3.392, p < 0.003, in podocytes with MC1R-mutant 
(n=4).  
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The means of cAMP-concentration 
in the non-stimulated podocytes of 
each type had a statistical 
significant difference with the 
values of 2.236 ± 0.645 pmol/well 
(MC1R) and 4.113 ± 0.3894 
pmol/well (MC1R-mutant), 
respectively. A calculation of the 
best-fit values in the non-linear fit 
gives starting values of 2.333 
pmol/well and 5.818 pmol/well, 
respectively. These lines are 
horizontal until the responses on 
stimulation and additionally, they 
are closely related to the values of 
the non-stimulated podocytes and 
can represent a baseline of non-
response (baseline) activity in the 
podocytes. The baseline of the 
MC1R-mutant is 2,49 times higher 
than the baseline of MC1R and this 
correspondents to 11,01% of the 
maximal MC1R-activity seen with stimulation of 1000 nM. 
 
Graph 5: The MC1R-mutant had a cAMP-concentration of 4.113 ± 0.3894 
pmol/well, which was statistical significant higher than the cAMP-
concentration of 2.236 ± 0.645 pmol/well in MC1R-podocytes (p < 0.05*, 
n=4). The calculated non-linear fit give a best fitted starting value of cAMP-
concentration at 5.818 and 2.333 pmol/well, respectively. With stimulation >1 
nM the MC1R-podocytes showed a dose-dependent relationship between 
MC1R-agonist and cAMP-concentration. The increase showed a statistical 
significance with stimulation of 100 – 1000 nM (p < 0.02* - <0.001***, n=4). 
The dose of 10 000 nM had a n-number of 2. With a stimulation of >100 nM 
the podocytes with MC1R-mutant also had a dose-dependent relation to cAMP-
concentration, (A). The two controls did not answer to stimulation; mean 
cAMP-level were 1.217 and 0.915 pmol/well, respectively (n=2), (B).  
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Cell	  viability	  
We ran three experiments: one in 24-wells plates and two in 12-wells plates. The 
experiment in 24-wells plate was interrupted and will not be reported. Neither MC1R-
agonist nor the concentration of puromycin in 10 µg/ml did show any effect on 
viability in any direction. According to the trend of data (n=2) in this direction it is 
uninteresting to do further analysis on the effects of MC1R-agonist itself or if the 
inhibitor should take away any protecting effects of the same. The parameters with 
MC1R-agonist (except in combination with puromycin 20 µg/ml) and puromycin 10 
µg/ml are therefore excluded in the analysis and any results will not be reported. The 
exception where MC1R-podocytes were exposed to both MC1R-agonist and 
puromycin 20 µg/ml, there was shown a higher viability with 173,6 % compared to 
those only exposed to puromycin 20 µg/ml (see graph 6). The podocytes 
overexpressing the MC1R-mutant did not show any protection from viability 
decreased by puromycin and neither further analysis with the MC1R-mutant will be 
done. Remaining is the effect of the inhibitor and the MC1R-podocytes exposed to the 
catalase specific inhibitor and puromycin showed in a dose-dependent fashion more 
viability than the ones exposed only to puromycin. The inhibitor in itself had a weak 
negative effect on the viability.  
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Graph 6: (n=2) Day 8. The podocytes with MC1R-mutant exposed to puromycin 20 µg/ml showed less viability, 34.51 % 
of control at day 0. MC1R-podocytes exposed to puromycin or puromycin and MC1R-agonist had a viability of 39.05 % 
and 67.66 %, respectively. MC1R-podocytes exposed to the inhibitor showed a weak dose-dependent decrease in viability: 
97.72 % and 92.31 %, respectively. The MC1R-podocytes exposed to both the inhibitor and puromycin showed reversed 
dose-response with higher viability; 74.14 % and 85.20 %, respectively. PAN20 = puromycin 20 µg/ml, BMS10 = MC1R-
agonist 10 nM, AMT10/20 = inhibitor 10 mM/20 mM. 
Discussion	  
On the whole my work evolved to be a development of experiment types and methods 
to get new approaches to future research. With this we have been able to dismiss 
some research questions and evaluate our strategies to examine the hypothesis about 
the role of catalase in the downstream mechanisms of MC1R-stimulation.  
From our examination of the regulation of catalase we could exclude a transcriptional 
dependence on and continued to examine catalase by regulation on protein level. Here 
we characterized a catalase specific inhibitor to evaluate the connection between 
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MC1R-activation and catalase activity. In other words, we intended to show that the 
mediation of the positive effects seen with MC1R-activation occurs through catalase, 
because podocytes with inhibited catalase will be more affected by damaging agents, 
despite the fact that MC1R is active. Our experiments showed that the inhibition of 
catalase was dose-dependent, meaning that the higher concentration of the inhibitor 
the podocytes were exposed to the less activity seen by catalase. However, to fully 
evaluate the relationship between inhibitor dose and catalase activity in podocytes, an 
increased number of repeats is required. This is also preferable to get higher strength 
to the results. Further, we also saw a recovery of the catalase activity over time and as 
referred to before, in previous experiments done by Aragon et al, 1991 [15], has 
shown a recovery in activity dependent on the disappearance of inhibitor in rat brain 
and rat liver. The concentrations used in the experiments were hereafter 10 or 20 mM.  
Further we analysed the constitutively active E94K MC1R-mutant and compared it to 
regular MC1R. As expected, MC1R showed a dose-dependent activity of intracellular 
cAMP increase and the mutant a constitutive cAMP accumulation, but not in the 
range we had predicted. According to previous studies done by Benned-Jensen et al 
[6], the activity of the mouse constitutive MC1R-mutant lies in a range around 50 % 
of stimulated MC1R-maximum, but our data of the previously untested human mutant 
were just showing an constitutive activity of 11 %. We saw an activity independent on 
stimulation (until doses ≥ 100 nM) that was 2,49 times higher than baseline in MC1R 
overexpressing podocytes, but not as high as we had expected. We also compared the 
catalase activity in podocytes overexpressing MC1R or MC1R-mutant, respectively. 
Contrary to our hypothesis, we were unable to see an increased catalase activity in the 
podocytes with MC1R-mutant over time. However, we saw the expected up-
regulation of catalase activity in podocytes overexpressing MC1R, stating the 
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connection we already knew from earlier experiments [2]: induced MC1R-activity 
leads to increased catalase activity. The inhibition of catalase by the specific inhibitor 
did affect both podocyte types with a decreased activity and with this we also got 
further evidence of its inhibition capacity.  
To summarize the different reasons behind the vague results and difficulties in 
drawing new conclusions from the catalase activity, we had technical problems, 
which lead to an inability to reproduce the experiments as we wanted. We identified 
unusable measurements to be either due to a recurrent fault in the concentration 
calculations or to an administration mistake concerning the standards in an Amplex 
Red® assay. The miscalculations of the concentrations were caused by a setting error 
in the software that summarized the protein concentrations (SoftMax® Pro) during 
the BCA-assay.  
To conclude the catalase activity experiments, the human mutant did not completely 
have the effect we wanted and future experiments are probably better done with 
mouse mutant, E92K. If this works better it could also be interesting for future mouse 
models. With genetically engineered mouse models it might be possible to analyse 
differences in downstream effects using constitutionally active MC1R. 
In addition, we tried to visualize the viability of podocytes overexpressing MC1R or 
MC1R-mutant, respectively and also in relation to catalase activity interfered with 
inhibitor. We assumed that the podocytes with the highest catalase activity should be 
most viable. With the use of the catalase inhibitor the role of catalase in podocyte 
protection could be further investigated. Through this we wanted to get better 
preconditions in the process to elucidate whether the protective effects of MC1R is 
dependent on catalase. Unfortunately, these experiments were followed by technical 
Master Thesis, Programme in Medicine  Sara Elofsson 
Melanocortin-1 Receptor-Stimulation and its Downstream Effector Mechanisms in Podocytes	  
30 
problems and therefore a very low number of repeated experiments were performed. 
According to the data we got, we did not see a higher viability in podocytes with 
MC1R-mutant exposed to puromycin compared to MC1R-podocytes with same 
exposure. This can be explained by the results from the experiment, previously 
discussed, with measurements of catalase activity in both kinds of podocytes. The 
MC1R-mutant did not show a higher catalase activity and the results of the viability 
assays do according to this make sense. The mutant did neither show increased 
catalase activity, nor increased protection against puromycin induced reduction of 
viability. The catalase inhibitor did not in itself induce significant loss of viability nor 
stronger effects together with puromycin compared to podocytes only exposed to 
puromycin. On the contrary, the podocytes with a combined treatment had higher 
viability than the other ones. The protection against puromycin induced viability loss 
is hard to explain, but it might be due to cross-reaction between the inhibitor and 
puromycin, despite studies suggesting otherwise [20]. In summary, our experiments 
does not provide enough evidence that catalase is the reason for the protection of 
podocytes against the harmful nephrotoxin puromycin, but we did gain knowledge 
regarding the regulation of catalase in podocytes following MC1R stimulation. 
Conclusion	  and	  Implications	  
We are in the process of investigating the signaling pathways activated by MC1R-
stimulation in podocytes. We believe that increased catalase activity plays an 
important role and we have been able to make some progress in examining the effects 
of catalase in podocytes.  
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In this thesis, we observed that catalase does not seem to be transcriptionally 
regulated by MC1R, and we assume the regulation to be at the protein level. We were 
able to dose-dependently inhibit the activity of catalase by using a specific inhibitor. 
In addition, we also overexpressed and characterized the human MC1R-mutant, 
E94K, which were shown to exhibit a low constitutive MC1R-activity. 
However, we still have a long way to go and we need to reach additional insights 
before understanding the bigger picture. If we can verify catalase to be the mediator 
of the ameliorating effects of MC1R-stimulation in nephrotic syndrome, this 
information can be used to plan new treatment strategies in future medical studies. 
Development of new treatments is desirable, since the treatment options available are 
scarce, ineffective and non-specific. MC1R-mediated changes in catalase activity 
might be a key to reach this goal.  
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Populärvetenskaplig	  sammanfattning	  
Vid njursjukdom med skador på beståndsdelar i njurens filtrationsenhet (exempelvis 
den specifika celltypen podocyter) utsöndras ämnen, som egentligen ska stanna kvar i 
blodet, till urinen. Det är främst ett proteinläckage som sker och därmed fås protein i 
urinen. Det finns många njursjukdomar av detta slag och en av dem är Membranös 
Nefropati (MN), med en incidens på 5-10 per miljon invånare per år och som kan leda 
till njuren helt slutar att fungera. MN saknar botande behandling men man har sett att 
behandling med ett visst hormon (signalsubstans), kallat adrenokortikotropt hormon 
(ACTH) ger ett minskat proteinläckage. Vi tror att behandling med ACTH påverkar 
de specifika filtrationscellerna (podocyterna) positivt genom att aktivera en 
signalmottagare (receptor) på deras cellyta, kallad Melanocortin-1 receptorn (MC1R). 
Denna receptor har setts leda till en ökning av aktiviteten hos det 
reaktionseffektiviserande proteinet (enzym) katalas som finns inne i filtrationscellerna 
och vi tror att detta är en viktig del av den positiva och förbättrande effekten man ser 
av ACTH. Katalas omvandlar skadliga föreningar till de oskadliga ämnena vatten och 
syre. Detta kan rädda en skadad cell från att dö och istället återhämta sig och återfå 
sin funktion.  
Genom att sätta in en förändrad variant av MC1R som alltid har en aktivitet 
(oberoende av signalsubstans) i podocyter som vi har i odling, ville vi kunna förenkla 
framtida experiment genom att slippa stimulera receptorn för att den ska fungera. 
Experiment visade dock att den alltid aktiva varianten av MC1R bara uppvisade 11 % 
av full aktivitet och den var därför inte intressant för fortsatta experiment.  
Vi analyserade även katalas roll i podocyterna och för att specifikt utreda det tittade vi 
på olika möjligheter till aktivitetsreglering av katalas. Först tittade vi på om 
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aktiviteten styrs via nyskapande av katalas eller om det finns regleringsmekanismer 
som påverkar redan existerande mängd av katalas. Dessutom tittade vi på hur 
podocyter mådde i relation till aktiviteten av katalas. Vi såg ingen ökad nyproduktion 
av katalas vid stimulering av MC1R och regleringen bör således inte bero på detta. Vi 
gick vidare till att studera om vi kunde påverka aktiviteten hos redan befintligt 
katalas. Genom att minska katalasaktiviteten kan man sammankoppla MC1R-
aktiveringen med katalas. Med andra ord ville vi testa om förmedlingen av den 
positiva effekten av MC1R-aktivering sker via katalas eftersom mindre 
katalasaktivitet leder till att cellen skadas/dör trots att MC1R är aktiverat. Våra 
experiment visade att aktivitetsminskningen av katalas är beroende av dos, vilket 
betyder att ju mer av aktivitetsminskaren vi tillförde desto svagare aktivitet uppvisade 
katalas.  
Den fulla omfattningen av MC1R-signalering och effekterna av katalas i podocyter är 
fortfarande okänd. Mer kunskap kan möjliggöra utformningen av nya läkemedel 
specifikt inriktade mot aktivering av MC1R eller påverkan på katalas. Positiva 
resultat skulle bli ett betydande bidrag till de få behandlingsalternativen som idag 
finns till patienter med proteinläckande njursjukdom.  
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Appendices	  
Activating	  pathways	  
We mainly found four different activating pathways of catalase and three of them 
were mediated on protein level by; 1) protein kinases, 2) Sirt1 – FoxO3a or 3) c-Abl 
and Arg. It also exist regulation at 4) transcriptional level. 
1.	  Protein	  kinases	  	  
Protein kinase A and C (PKA resp. PKC) and Casein kinase II (CKII) have been 
shown to increase catalase activity in human erythrocytes [21]. PKC requires longer 
time than PKA (rapid change) to reach the plateau where catalase activity was 
increased but there is also a difference between different PKC isozymes. PKC 
consists of several isozymes and their ability of modulation is due to the presence or 
absence of PKC activators. The most effective in both presence and absence of these 
is PKCζ. Because of the ability to modulate in the absence of activators PKCζ is 
likely to act as a constitutive modulator of catalase activity in most cell types. PKA 
and PKCζ have also a synergistic modulation effect. 
Catalase is constituted of four identical 60 kDa subunits and several minor 
components. These minor components are probably phosphorylated and are proposed 
to be one of the reasons behind the protein kinase-dependent activity increase. This 
leads to changes in electrostatic folding of pre-phosphorylated 60 kDa subunit which 
affects catalase’s active center. 
A potent PKA activator is forskolin and it has shown a proportional increase in the 
expression of one of the minor components, the immunoreactive 110 kDa component. 
The major 60 kDa subunit did only show a weak increase in expression. Forskolin-
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dependent increase of catalase is therefore likely to be associated with an expression 
increase of 110 kDa component and maybe together with the phosphorylation by 
PKA. 
PKA	  regulation	   
PKA itself is an ATP-dependent kinase and is allosterically activated by cAMP, 
which is formed through cyclization of ATP (see figure I) [22]. Conversion of ATP is 
done by activation of a G-coupled receptor, where the activated G-protein in turn 
activates adenylate cyclase. Adenylate cyclases can also be activated by e.g. Forskolin 
[23]. Down-regulation of PKA is due to a negative feedback mechanism on cAMP. 
cAMP is hydrolyzed, in the action of phosphodiesterase, to become 5’-AMP [24]. 
PKC	  regulation	   
PKC is activated by a phospholipid as phosphatidylserine, diacylglycerol (DAG) and 
Ca²+ (see figure I) [25].  
 
Figure I: Overview of intracellular mechanisms activated due to stimulation of G-coupled 
receptor or adenylyl cyclase. 
Master Thesis, Programme in Medicine  Sara Elofsson 
Melanocortin-1 Receptor-Stimulation and its Downstream Effector Mechanisms in Podocytes	  
III 
MAPK-­‐pathway 
 
Figure II: Overview of intracellular mechanisms of the MAPK-pathway activated due to mitogenic or damaging stimulation. 
There are two different Mitogen-Activated Protein Kinase, MAPK-pathways (see 
figure II) [19, 26, 27]. p38MAPK increase the catalase activity and protein amount as 
well as mRNA levels. Growth factor PDGF-BB binds to the PDGF-receptor. This 
receptor or the creation of Ras-Raf complex are inhibited by PKA and through this 
PKA decrease cell growth. 
The cells used in these studies of the MAPK-pathway were; a) HP100 (Hydrogen 
Peroxide-resistant cells) as well as the cells they are derived from, human leukemia 
HL60 cells, b) V79 lung fibroblasts, c) aortic smooth muscle cells and d) cultured 
mesangial cells exposed to high glucose (probably from humans with diabetic 
nephropathy). 
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2.	  Sirt1	  –	  FoxO3a	  	  
Sirt1 – stands for sirtuin, Silent Information Regulator Two (Sir2) protein – is a 
NAD+-dependent protein deacetylase which deacetylate many target proteins, e.g. p53 
and forkhead (FoxO) transcription factors [28, 29]. These proteins provide protection 
against apoptosis and play an essential role in mediating the survival of a lot of cell 
types. When Sirt1 is inhibited in human renal tubular cells under normal conditions 
apoptosis was induced and the expression of catalase was up-regulated. An 
overexpression of Sirt1 down-regulates catalase-expression. H2O2-treatment induces 
acute oxidative stress and the Sirt1-expression was up-regulated at the same time as 
the catalase-expression also was up-regulated, in contrary to the results from previous 
experiment. This leads to the conclusion that Sirt1 regulates the catalase-expression 
depending on the underlying conditions; if the cell is affected with H2O2 catalase 
expression is increased via Sirt1 but the other way around decreased. 
! H2O2-affected cells " ↑ catalase via Sirt1 
! Non H2O2-affected cells " ↓ catalase via Sirt1 
This situation is due to FoxO3a (deacetylated by Sirt1), which differs in localization 
in the cell dependent on H2O2-levels:  
! Absence of H2O2" dominantly in the cytoplasm  
! Presence of H2O2" translocation to the nucleus  
On the contrary Sirt1 is localized in both cytoplasm and nucleus under basal or H2O2-
treated conditions. When H2O2 induces translocation of FoxO3a to the nucleus it co-
localizes and forms a complex with Sirt1, which coincidently deacetylates FoxO3a. 
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Figure 7: Summary of Sirt1 
This complex tips the cell away from apoptosis towards higher stress resistance with 
induced cell cycle arrest and an up-regulated catalase expression. 
The cell cycle arrest gives the cell more time to detoxify ROS and repair damaged 
DNA. Accordingly, the stress resistance effects of FoxO3a are Sirt1-dependent and 
therefore the regulation of catalase expression is dependent on the presence or 
absence of FoxO3a in the nucleus during conditions of oxidative stress. 
Sirt1	  regulation	  	  
Sirt1 is encoded by the SIRT1 gene (see figure III) [30]. Lamin A binds to and 
activates Sirt1 [31]. Resveratrol enhances the activity indirectly by increasing the 
expression of SIRT1 and enhances the binding between Sirt1 and Lamin A.  
AROS, active regulator of SIRT1, 
binds directly to the N-terminus of 
Sirt1. AROS enhances Sirt1-mediated 
deacetylation of p53, which thereby 
inhibits p53 transcriptional activity. 
Overexpression of AROS represses the 
p53 response and favours cell survival.  
Stress activates p53 protein which 
through other gene expressions down-
regulates SIRT1 and thereby forming a 
regulatory feed-back loop.  
Figure III: Overview of the Sirt1-regulation 
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3.	  c-­‐Abl	  and	  Arg	  tyrosine	  kinases	  
The activity of c-Abl and Arg tyrosine kinases are up-regulated due to oxidative stress 
and H2O2 induces the binding of them to catalase (see figure IV) [20]. The SH3 
domain of respective kinase binds to catalase at PFNP (proline-rich) site and 
phosphorylate catalase at Y231 and Y386. c-Abl and Arg are required for catalase 
activity and both c-Abl- and Arg-deficient cells are hypersensitive to H2O2-induced 
apoptosis. By contrast there is also evidence indicating that c-Abl- and Arg-activation 
by H2O2 is necessary for 
induction of apoptosis and this 
is described further under the 
part about degradation 
pathways.  
c-­‐Abl	  and	  Arg	  regulation	  
ROS-induced apoptosis 
activates them both (see figure 
IV). In the case of the 
activation of c-Abl, it is PKCδ-
dependent and associated with 
the translocation of c-Abl to 
mitochondria and the release of 
cytochrome c. Arg interacts 
with the pro-apoptotic Siva-1 
protein, which is phosphorylated, and is also translocated to mitochondria. 
A 
 
B 
 
Figure IV: Overview of the C-Abl (A) and the Arg-C-Abl-regulation (B), respectively 
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4.	  Transcriptional	  	  
The stimulating protein 1 (Sp1) and CCAAT-recognizing factors regulates catalase at 
the transcriptional level and EgrSp-70 (overlapping recognition sequence for Egr-1 
and Sp1) have critical roles in the regulation of catalase gene transcription (see figure 
V) [18, 32]. 
HP100 (Hydrogen Peroxide-resistant, HP100, cells are derived from human leukemia 
HL60 cells) got much higher levels of nuclear Sp1 and NF-Y than HL60. Sp-1 and 
WT1/Egr-related factor have low binding in HL60 cells. WT1 (Wilm’s tumor 
suppressor 1) is a negative transcription regulator of catalase.  
Sp1 associates with the EgrSp-70 
and binds to the GC box (core 
promoter element) here. This 
leads to the recruiting of RNA-
polymerase II. Sp1 is expressed 
in high levels in HP100 nuclei 
and this activates core catalase 
promoter in cooperation with 
CCAAT-recognizing factors 
(CCAAT-92 is a transcriptional 
enhancer in HP100 cells). NF-Y 
associates with the CCAAT 
element. 
 
 
Figure V: Overview of the regulation of Sp1. 
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X-ray irradiation in HP100 cells leads to reduction in catalase mRNA levels by 
inducing association of WT1/Egr-related factor with the EgrSp-70 at the core 
promoter of the catalase gene. The X-ray inducible WT1/Egr-related factor may 
disturb or compete with the trans-activating ability of Sp1, which leads to inactivation 
of the core promoter. 
Inhibiting	  pathways	  
The only inhibitor we found to be catalase specific was 3-amino-1, 2, 4-triazole, 3-
AT/AMT/ATZ [14]. Hereinafter referred to as catalase inhibitor. 
Aragon et al, 1991, observed brain and liver catalase in Male Long Evans rats, who 
got the catalase inhibitor administrated intraperitoneally [15]. They showed a dose- 
and time-dependent inhibition. The recovery of catalase activity in respective tissues 
was associated with the disappearance of the catalase inhibitor and consequently this 
was found to be an irreversible inhibitor. They also investigated the amounts of H2O2 
in the tissues and concluded a dependence of the catalase inhibitor activity and rate of 
generated H2O2. The catalase inhibitor seems to bind a compound of catalase and 
H2O2. Without H2O2 no inhibition is observed, neither does it inhibit in the presence 
of alcohol, because alcohol compete to bind the same site in the catalase-H2O2 
compound.  The difference between them is that the catalase inhibitor bind 
irreversibly [16]. Moreover, and on the contrary, they also refer to previous studies, 
including one by William RN et al [17] where they are suggesting the catalase 
inhibitor to be indirect in action rather than having a direct effect on catalase. 
According to this the catalase inhibitor would undergo metabolic transformation, in 
the topic tissue, to become an active inhibitor. 
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To have guidance in reasonable administration doses of the catalase inhibitor directly 
to cells in cell culture further studies were investigated. Nenoi M. et al, 2001, used 
HP-100 cells (H2O2-resistant variants derived from human leukemia HL60 cells) 
which were incubated during 2 hours with the concentration of 25mM the catalase 
inhibitor [18]. HP-100 cells were also used in another study by Hachiya M. et al, 
2005, and they incubated with 20 mM instead and during one hour [19].  
Degradation	  pathways	  	  
ROS-induced apoptosis is p53-dependent [20, 33].  
Previously c-Abl- and Arg-mediated phosphorylation has been mentioned to be 
necessary in stimulation of catalase activity and now this has also been shown to be of 
importance in the degradation process of catalase (see figure VI). This is partly 
described by the level of ROS; low levels leads to phosphorylation of catalase but if 
the levels continue to increase c-Abl and Arg dissociate from catalase and stimulate 
an apoptopic response instead.  
This means that the anti-apoptopic response of catalase is due to the ROS-levels. 
When c-Abl and Arg dissociate, the catalase activity is decreased either by: 
1) Tyrosinephosphatases that desphosphorylate Y231-P and/or Y386-P " 
inactivation 
or 
2) Targeting of phosphorylated catalase for ubiquitination " degradation 
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Figure VI: Overview of the degradation pathway of catalase.	  
catalase has been shown to be degradated by the 26S proteosome and the targeting for 
the Ub-proteosome pathway is regulated by c-Abl and Arg through tyrosine 
phosphorylation of the same sites as in activation (Y231 and Y386). C-Abl and Arg 
regulates catalase ubiquitination and degradation as well as its activation. 
H 2O2 -induced response of catalase levels is attenuated with Lactacystin (proteosomal 
inhibitor) and leads to less catalase degradation, which in turn results in lower ROS. 
In turn proteosomal degradation of catalase results in increasing ROS and thereby cell 
death by apoptosis or necrosis. 
c-Abl and Arg are protecting the cell from oxidative stress by stimulating catalase 
activity but when the ROS-levels goes unmanageable they induce catalase 
degradation instead which results in cell death. The degradation of catalase might 
increase the speed of the apoptotic process. 
By this they function as a potential switch, which controls the catalase levels and 
redox balance.  
